This is the authors' abstract. We don't add key points for this paper.
1018 Background: Triple negative breast cancer (TNBC) shares molecular characteristics with BRCA1-/- breast cancer (BC). Preclinical and clinical data show that BRCA1-/- BC and TNBC are sensitive to inhibition of PARP1, an enzyme necessary for DNA repair and other critical cell functions. This phase 1 study evaluated the tolerability of olaparib, a potent PARP1 inhibitor, combined with weekly paclitaxel in patients with metastatic TNBC. This trial served as a safety evaluation to be followed by a phase II trial after tolerability was determined. Methods: Eligible patients (pts) had ≤ 1 prior cytotoxic regimens for ER-, PR-, and HER2- metastatic BC. Pts were treated with olaparib 200mg capsules PO BID continuously combined with paclitaxel 90mg/m2 IV weekly for 3 of 4 weeks. At this dose, a significant number of pts had delays due to neutropenia, thus a second cohort of 10 pts was enrolled with an amendment to the protocol to allow for GCSF (300 μ g SC days 3-5) as secondary prophylaxis following weekly paclitaxel to maintain dose intensity. Results: Nineteen pts were enrolled (median age 49.0 years [range 36 - 71 years]); all PS 0-1; median one prior metastatic chemo regimen; 15 pts had prior taxane chemotherapy. The most frequent (n) grade 1-2 adverse events were fatigue (10; grade 3 > 1/10), nausea (10) diarrhea (12). Grade 1-2 neutropenia was reported in 5 pts, grade 3 in 5 pts, grade 4 in 1 pt, and febrile neutropenia in 1 pt (grade 3). Neutropenia in the second cohort was managed with GCSF in 3/10 pts, but 2/3 pts had recurrent grade 2 neutropenia despite GCSF prophylaxis. Using investigator-assessed RECIST response, 7 pts (37%) had confirmed partial responses (PRs), 10 pts (53%) had confirmed+ unconfirmed PRs. Data on PFS will be presented. Conclusions: The combination of olaparib and weekly paclitaxel was well tolerated, but acceptable dose intensity (i.e., missed/delayed doses) was not achieved due to neutropenia despite secondary prophylaxis with GCSF. This preliminary analysis demonstrated promising efficacy. Alternative schedules and dosing of olaparib are being considered. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca AstraZeneca AstraZeneca AstraZeneca, GlaxoSmithKline, Novartis, Roche AstraZeneca
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dent et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: